Objective To analyze surveillance data for adverse events following immunization(AEFIs)in China during 2021-2022.Methods We obtained data on AEFI reports and numbers of post-marketed vaccine doses administered during 2021-2022 from the Chinese Immunization Information Management System(excluding emergency-use or conditional-market vaccines).We analyzed characteristics and reported incidences of AEFIs using descriptive epidemiological method.Results A total of 323 627 AEFI cases for 41 vaccines were reported in China during 2021-2022,yielding an overall incidence of 32.52 cases per 100 000 doses administered,with 0.15 per 100 000 doses(1 468 cases,0.45％)for serious AEFIs.The incidence per 100 000 doses was 31.07(309 163 cases,95.53％of all cases)for common adverse reactions and 1.14(11 381 cases,3.52％)for rare adverse reactions,with 0.08(759 cases,0.23％)for serious adverse reactions.Incidences per 100 000 doses for anaphylactic rash,angioedema,and thrombocytopenic purpura/thrombocytopenia were 0.96(9 528 cases),0.02(232 cases),and 0.02(230 cases),respectively.Conclusions The reported incidence of AEFIs deceased slightly in China in 2021-2022.Most adverse reactions were mild,and serious reactions were extremely rare.
VaccineAdverse event following immunizationSurveillance
万方数据
维普
